NCT05836870

Brief Summary

To learn if a supervised exercise program during chemotherapy treatments can help to improve outcomes in patients who have been diagnosed with pancreatic cancer

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at below P25 for phase_3 pancreatic-cancer

Timeline
80mo left

Started Jul 2023

Longer than P75 for phase_3 pancreatic-cancer

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress31%
Jul 2023Dec 2032

First Submitted

Initial submission to the registry

April 20, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

May 1, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

July 18, 2023

Completed
7.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2030

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2032

Last Updated

March 2, 2026

Status Verified

February 1, 2026

Enrollment Period

7.5 years

First QC Date

April 20, 2023

Last Update Submit

February 26, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Safety and adverse events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    thorugh study completion; an average of 1 year.

Study Arms (2)

Group A-Enhanced Usual Care

EXPERIMENTAL

Participants will be given general recommendations to increase physical activity and improve nutrition before surgery.

Other: Enhanced Usual Care

Group B-Tele-supervised resistance exercises

EXPERIMENTAL

Participants will take part in a monitored exercise program. The study team will provide more instructions and information about the program

Behavioral: Tele-supervised resistance exercises

Interventions

Participants will receive general recommendations to maintain physical activity.

Group A-Enhanced Usual Care

Participants will take part in a monitored exercise program.

Group B-Tele-supervised resistance exercises

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Provision of signed and dated informed consent form
  • Biopsy-proven pancreatic adenocarcinoma, resectable/borderline resectable (T1-3, N0-2, M0)
  • Recommended to receive 2-6 months of neoadjuvant chemotherapy followed by surgical resection including participants who have not yet received chemotherapy and participants who have already received their first cycle of chemotherapy.
  • Willingness to adhere to the Tele-PancFit study intervention
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Able to schedule baseline (T0) appointment for fitness testing and program teaching at the fitness testing location at each study site or able to schedule remote fitness testing and program teaching:
  • Behavioral Research and Treatment Center (BRTC) at MDACC
  • Exercise Physiology laboratory in the Department of Kinesiology and Health Education at UT Austin
  • Outpatient Rehabilitation gymnasium at Banner MDA
  • Able to understand the description of the study, exercise program, and willing to participate
  • Home or community access to wireless internet (Wi-Fi) and agreement to engage with study personnel for real-time tele-RT sessions
  • Age ≥ 18
  • Meet all screening requirements (described below).

You may not qualify if:

  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Non-English speaking
  • Has participated in regular RT (RT for all major muscle groups at least twice per week) throughout the month prior to recruitment
  • Unable to complete the baseline assessment questionnaires or functional assessments
  • Screen failure for exercise safety based on PAR-Q and/or PROMIS questions as described in section 4.4 (Screening Procedure).
  • Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV).
  • Recent fracture or acute musculoskeletal injury that precludes the ability to weight bear fully on all 4 limbs in order to participate in an exercise intervention.
  • Numeric pain rating scale of ≥7 out of 10
  • Myopathic or rheumatologic disease that impacts physical function.
  • (Females only) Known pregnancy, as communicated to study personnel by clinicians in GI Medical Oncology; females of childbearing potential receive advice to use methods of contraception per usual care.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Officials

  • An Ngo-Huang, DO

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 20, 2023

First Posted

May 1, 2023

Study Start

July 18, 2023

Primary Completion (Estimated)

December 31, 2030

Study Completion (Estimated)

December 31, 2032

Last Updated

March 2, 2026

Record last verified: 2026-02

Locations